Bivalirudin
- Generic Name
- Bivalirudin
- Brand Names
- Angiomax
- Drug Type
- Small Molecule
- Chemical Formula
- C98H138N24O33
- CAS Number
- 128270-60-0
- Unique Ingredient Identifier
- TN9BEX005G
- Background
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activat...
- Indication
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
- Associated Conditions
- Thrombosis
- Associated Therapies
- -
Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 6016
- Registration Number
- NCT03822975
- Locations
- 🇨🇳
Linquan County Peoples Hospital, Fuyang, Anhui, China
🇨🇳Bengbu Second People's Hospital, Bengbu, Anhui, China
🇨🇳Fu Yang People'S Hospital, Fuyang, Anhui, China
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 2989
- Registration Number
- NCT03664180
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Reduce Bolus Injection of Bivalirudin
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Han Yaling, MD
- Target Recruit Count
- 204
- Registration Number
- NCT03588611
- Locations
- 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China
Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Qian Gong
- Target Recruit Count
- 200
- Registration Number
- NCT03567408
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 165
- Registration Number
- NCT03537586
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03532399
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO
- Conditions
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03318393
- Locations
- 🇺🇸
Children's Medical Center, Dallas, Texas, United States
Bivalirudin in Acute Myocardial Infarction
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 380
- Registration Number
- NCT02897037
- Locations
- 🇨🇳
Department of Cardiology，General Hospital of Shenyang Military Region, Shanyang, Liaoning, China
Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 1770
- Registration Number
- NCT02787317
- Locations
- 🇨🇳
ChinaPLAGH, Beijing, Beijing, China
Bivalirudin Infusion for Ventricular Infarction Limitation
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 78
- Registration Number
- NCT02565147
- Locations
- 🇫🇷
Hopital Ambroise Paré, Boulogne Cedex, France
🇫🇷Hospital Lariboisière, Paris, France
🇳🇱VUMC Amsterdam, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.